Insmed, Inc., a biopharmaceutical company, provided a significant charitable contribution to NTM Info & Research to further support our mission.
“We were happy to help recruit patients for their Phase II study of ARIKAYCE(™), an inhaled liposomal form of Amikacin for patients with refractory NTM disease,” said Philip Leitman, president of NTMir.
“We’re pleased to continue building the relationship between NTM Info & Research, the patient advocacy organization for pulmonary NTM disease, and Insmed, a company dedicated to improving the lives of patients battling serious orphan lung diseases by developing novel, targeted inhalation therapies for patients with critical unmet needs.”
“This unprecedented support has allowed us to further our mission by revising and reprinting our flagship publication, “Insight: A Patient’s Perspective,” which has seen 12,000 copies circulated in the last 18 months, and to send representatives of the organization to this year’s ATS International Conference in San Diego, CA, where they participated in the ATS Patient Advisory Roundtable activities, partnered with Insmed to disseminate pamphlets to attendees to raise awareness of NTM, attended scientific sessions and met with additional potential partners interested in NTM disease education,” added Mr. Leitman.
“We’re grateful for Insmed’s interest in developing new and better treatments for NTM lung disease, and we look forward to working with them to advance awareness of this illness.”